Online first
Clinical vignette
Published online: 2024-11-26

open access

Page views 45
Article views/downloads 35
Get Citation

Connect on Social Media

Connect on Social Media

Pasireotide treatment in giant prolactinoma resistant to dopamine agonists

Maria Komisarz-Calik1, Grzegorz Zieliński2, Karol Ciszek1, Anna Bogusławska1, Alicja Hubalewska-Dydejczyk1, Aleksandra Gilis-Januszewska1

Abstract

Not required for Clinical Vignette.

Article available in PDF format

View PDF Download PDF file

References

  1. Maiter D, Delgrange E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol. 2014; 170(6): R213–R227.
  2. Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023; 19(12): 722–740.
  3. Zielinski G, Ozdarski M, Maksymowicz M, et al. Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery. Front Endocrinol (Lausanne). 2020; 11: 439.
  4. Lasolle H, Vasiljevic A, Borson-Chazot F, et al. Pasireotide: A potential therapeutic alternative for resistant prolactinoma. Ann Endocrinol (Paris). 2019; 80(2): 84–88.
  5. Coopmans EC, van Meyel SWF, Pieterman KJ, et al. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. Eur J Endocrinol. 2019; 181(2): K21–K27.